



## Artery Research

ISSN (Online): 1876-4401

ISSN (Print): 1872-9312

Journal Home Page: <https://www.atlantis-press.com/journals/artres>

---

### **HIV and atherosclerosis: Heterogeneity of studies results**

Cristina Giannattasio, Alessandro Maloberti, Andrea Gori

**To cite this article:** Cristina Giannattasio, Alessandro Maloberti, Andrea Gori (2013) HIV and atherosclerosis: Heterogeneity of studies results, Artery Research 7:2, 81–83, DOI: <https://doi.org/10.1016/j.artres.2013.02.001>

**To link to this article:** <https://doi.org/10.1016/j.artres.2013.02.001>

Published online: 7 December 2019



## LETTER TO THE EDITOR

**HIV and atherosclerosis: Heterogeneity of studies results**

Dear Editor,

We appreciated the article by Palios and colleagues published on your journal.<sup>1</sup> One notable point of the article is the detailed review of cardiovascular disease in HIV-infected subjects. While a certain degree of selection is necessary for such a kind of papers, we noticed some incompleteness on cited data on carotid atherosclerosis.

In recent years a large number of paper had focused on Intima-Media-Thickness (IMT) in HIV-positive subjects. Taking into consideration only studies of comparison with the general population, and among these, only the studies with at least 50 subjects enrolled (supposed as the minimum number needed to make a good IMT comparison study) results are not homogeneous. Some studies found an higher IMT value in HIV than in controls (and they were partially listed by Palios)<sup>2–9</sup> while others found the opposite result.<sup>10–12</sup>

One possible explanation of this difference is the heterogeneity in subjects selection between studies. Some studies have enrolled subjects treated with antiretroviral,<sup>3,5,7,11</sup> while others enrol only never treated subjects.<sup>10</sup> Some researcher excludes subjects with cardiovascular disease<sup>3</sup> while others do not.<sup>4,7</sup>

Methodological difference in acquisition of IMT is a second possible explanation of the not homogeneous results. Some protocols acquire IMT on several carotid artery (CA) segment (common, bulb and internal) and use both proximal and far wall.<sup>2–4</sup> Instead others measure IMT only at the far wall of the common CA.<sup>5–12</sup>

It is possible that these methodological differences alone, or together with the difference in inclusion criteria, lead to the different results obtained. As it is shown in Table 1, when measurements are acquired in different CA segments, results are in favour of a broader difference in IMT (more than 0.1 mm) between HIV+ and controls.<sup>2–4</sup> On the contrary, this difference is less broad (less than 0.1 mm)<sup>5–9</sup> or it does not appear at all<sup>10–12</sup> when only common CA is considered.

Notable Grunfeld et al.<sup>13</sup> measure IMT both in internal and in common CA. In the internal CA they found an higher value in HIV+ in comparison with controls, while data on common CA were similar in the two groups. It has to be noticed that in general population IMT has a higher reproducibility when acquired in the common CA.<sup>14,15</sup>

The inhomogeneity of data published extends also to endothelial function. Some studies show an impairment in Flow Mediated Dilatation<sup>16–19</sup> and others do not.<sup>20–22</sup> When specific antiretroviral drugs were considered old generation protease inhibitors (PI) has determine endothelial dysfunction<sup>23–26</sup> while newer PI do not.<sup>27–29</sup>

Because of the increasing cardiovascular morbidity and mortality in HIV-subjects, the large interest of the scientific

**Table 1** Results of the principal IMT comparison studies on HIV-positive subjects.

Reference	Number of patients	IMT measurement methods	IMT value
<i>Studies with a broad (more than 0.1 MM) IMT difference</i>			
Hsue PY, <sup>2</sup> Circulation 2004.	148 HIV+ (A) 63 controls (B).	Near and far wall of the common, bulb and internal carotid artery.	0.91 (A) and 0.74 (B).
Hsue PY, <sup>3</sup> AIDS 2006.	93 HIV+ on ART (A) 37 controls (B).	Near and far wall of the common, bulb and internal carotid artery.	0.95 (A) and 0.68 (B).
Ross AC, <sup>4</sup> Clin Infect Dis 2009.	73 HIV+ (A) 21 controls (B).	Near and far wall of the common, bulb and internal carotid artery.	1.25 (A) and 1.05 (B).
<i>Studies with a less broad (less than 0.1 MM) IMT difference</i>			
Papita A, <sup>5</sup> Med Ultrason 2011.	65 HIV+ on ART (A) 36 controls (B).	Far wall of the common carotid.	0.6 (A) and 0.51 (B).

(continued on next page)

Table 1 (continued)

Reference	Number of patients	IMT measurement methods	IMT value
Charakida M, <sup>6</sup> <i>Circulation</i> 2005.	83 HIV+ (A) 59 controls (B).	Far wall of the common carotid.	0.6 (A) and 0.5 (B).
Johnsen S, <sup>7</sup> <i>J Clin Endocrinol Metab</i> 2006.	44 HIV+ on ART on PI (A) 40 HIV+ on ART not on PI (B) 86 controls (C).	Far wall of the common carotid.	0.65 (A), 0.61 (B) and 0.61 (C).
Lorenz MW, <sup>8</sup> <i>Atherosclerosis</i> 2008.	292 HIV+ (A) 1168 controls (B).	Far wall of the common carotid.	0.74 (A) and 0.72 (B).
Giuliano Ide C, <sup>9</sup> <i>Coron Artery Dis</i> 2008.	83 HIV+ (A) 83 controls (B).	Far wall of the common carotid.	0.48 (A) and 0.42 (B).
<i>Studies with no difference in IMT measurements</i>			
Bongiovanni M, <sup>10</sup> <i>J Antimicrob Chemother</i> 2008.	53 HIV+ naive (A) 133 HIV+ on ART (B) 54 controls (C).	Far wall of the common carotid.	0.58 (A), 0.64 (B) and 0.65 (C).
Currier JS, <sup>11</sup> <i>AIDS</i> 2005.	44 HIV+ on ART on PI (A) 44 HIV+ on ART not on PI (B) 44 controls (C).	Far wall of the common carotid.	0.69 (A), 0.71(B) and 0.69 (C).
Kaplan RC, <sup>12</sup> <i>AIDS</i> 2008.	Women: 1231 HIV+ (A) 496 controls (B) Men: 600 HIV+ (C) 325 controls (D).	Far wall of the common carotid.	0.72 (A), 0.71 (B), 0.75 (C) and 0.77 (D).

IMT = Intima Media Thickness.

community on early atherosclerosis in this framework do not surprise.

With this brief letter we want to underline that the issue is not completely defined and understood and there are still a lot of uncertainties. The article of Palios et al. has the merit to focus on the importance of IMT and endothelial function in understanding atherosclerosis progression in HIV.

## References

- Palios J, Ikonomidis I, Lekakis J, Anastasiou-Nana M. Atherosclerotic vascular disorders in HIV infected patients. *Artery Res* 2011;5:81–90.
- Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. *Circulation* 2004 Apr 6;109(13):1603–8.
- Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. *AIDS* 2006 Nov 28;20(18):2275–83.
- Ross AC, Rizk N, O’Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. *Clin Infect Dis* 2009 Oct 1;49(7):1119–27.
- Papita A, Albu A, Fodor D, Itu C, Cârstina D. Arterial stiffness and carotid intima-media thickness in HIV infected patients. *Med Ultrason* 2011;13(2):127–34.
- Charakida M, Donald AE, Green H, Storry C, Clapson M, Caslake M, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. *Circulation* 2005 Jul 5;112(1):103–9.
- Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. *J Clin Endocrinol Metab* 2006 Dec;91(12):4916–24.
- Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. *Atherosclerosis* 2008 Feb;196(2):720–6.
- Giuliano Ide C, de Freitas SF, de Souza M, Caramelli B. Sub-clinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study. *Coron Artery Dis* 2008 May;19(3):167–72.
- Bongiovanni M, Casana M, Cicconi P, Pisacreta M, Codemo R, Pelucchi M, et al. Predictive factors of vascular intima media thickness in HIV-positive subjects. *J Antimicrob Chemother* 2008 Jan;61(1):195–9.
- Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al., AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. *AIDS* 2005 Jun 10;19(9):927–33.
- Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. *AIDS* 2008 Aug 20;22(13):1615–24.
- Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection:

- carotid intima-medial thickness measurements from the FRAM study. *AIDS* 2009 Sep 10;23(14):1841–9.
14. Freire CM, Ribeiro AL, Barbosa FB, Nogueira AI, de Almeida MC, Barbosa MM, et al. Comparison between automated and manual measurements of carotid intima-media thickness in clinical practice. *Vasc Health Risk Manag* 2009;5:811–7.
  15. Wong M, Edelstein J, Wollman J, Bond MG. Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. *Arterioscler Thromb* 1993;13(4):482–6.
  16. Oliviero U, Bonadies G, Apuzzi V, Foggia M, Bosso G, Nappa S, et al. Human immunodeficiency virus per se exerts atherogenic effects. *Atherosclerosis* 2009 Jun;204(2):586–9.
  17. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. *AIDS* 2004 Apr 30;18(7):1037–41.
  18. Lekakis J, Tsiodras S, Ikonomidis I, Palios J, Poulakou G, Rallidis L, et al. HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. *Clin Sci (Lond)* 2008 Sep;115(6):189–96.
  19. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, et al. Endothelial function in HIV-infected persons. *Clin Infect Dis* 2006 May 1;42(9):1325–32.
  20. Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? *QJM* 2003 Nov;96(11):825–32.
  21. Dubé MP, Shen C, Mather KJ, Waltz J, Greenwald M, Gupta SK. Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. *AIDS Res Hum Retroviruses* 2010;26(8):847–54.
  22. Lebech AM, Kristoffersen US, Wiinberg N, Kofoed K, Andersen O, Hesse B, et al. Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. *Eur J Nucl Med Mol Imaging* 2008 Nov;35(11):2049–58.
  23. Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. *Am Heart J* 2005 Nov;150(5):933.
  24. Dubé MP, Gorski JC, Shen C. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. *Cardiovasc Toxicol* 2008 Mar;8(1):15–22.
  25. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. *AIDS* 2009 Sep 24;23(15):2021–7.
  26. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. *Circulation* 2001 Jul 17;104(3):257–62.
  27. Dubé MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. *Clin Infect Dis* 2008 Aug 15;47(4):567–74.
  28. Grubb JR, Dejam A, Voell J, Blackwelder WC, Sklar PA, Kovacs JA, et al. Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects. *J Infect Dis* 2006 Jun 1;193(11):1516–9.
  29. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, et al., ACTG 5152s Study Team. Endothelial function in human immunodeficiency virus-infected antiretroviral-naïve subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. *J Am Coll Cardiol* 2008 Aug 12;52(7):569–76.

Cristina Giannattasio\*

Cardiology IV Unit, Niguarda Ca Granda Hospital and  
Milano-Bicocca University, Piazza Ospedale  
Maggiore 3, 20162 Milano, Italy

Alessandro Maloberti

Internal Medicine Department, San Gerardo Hospital,  
Monza, Italy  
E-mail address: a.maloberti@campus.unimib.it

Andrea Gori

Infectious Disease Department, San Gerardo Hospital,  
Monza, Italy  
E-mail address: andrea.gori@unimib.it

\*Corresponding author. Tel.: +39 02 64 44 21 41;  
fax: +39 02 64 44 25 66.

E-mail address: cristina.giannattasio@unimib.it  
(C. Giannattasio)

6 June 2012